RVV.CN Stock - Revive Therapeutics Ltd.
Unlock GoAI Insights for RVV.CN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-248 | $-328 | $-434 | $-578 | $-775 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-1,648,714 | $-3,286,044 | $-5,521,013 | $-17,833,026 | $-18,495,720 |
| Net Income | $-11,011,319 | $-5,618,622 | $-6,320,900 | $-17,833,628 | $-20,197,784 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.03 | $-0.01 | $-0.02 | $-0.06 | $-0.08 |
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Visit WebsiteEarnings History & Surprises
RVV.CNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 27, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | — | — | — | — |
Q4 2025 | Nov 27, 2025 | — | — | — | — |
Q2 2025 | May 30, 2025 | — | — | — | — |
Q2 2025 | May 28, 2025 | — | $-0.00 | — | — |
Q1 2025 | Feb 26, 2025 | — | $-0.00 | — | — |
Q4 2024 | Nov 27, 2024 | — | $-0.00 | — | — |
Q2 2024 | May 30, 2024 | — | $-0.01 | — | — |
Q2 2024 | May 30, 2024 | — | $-0.00 | — | — |
Q1 2024 | Feb 28, 2024 | — | $-0.00 | — | — |
Q4 2023 | Nov 29, 2023 | — | $-0.00 | — | — |
Q2 2023 | May 30, 2023 | — | $-0.00 | — | — |
Q2 2023 | May 29, 2023 | — | $-0.01 | — | — |
Q1 2023 | Feb 28, 2023 | — | $-0.00 | — | — |
Q4 2022 | Nov 25, 2022 | — | $-0.01 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.01 | — | — |
Q2 2022 | May 30, 2022 | — | $-0.02 | — | — |
Q1 2022 | Mar 1, 2022 | — | $-0.01 | — | — |
Q4 2021 | Nov 29, 2021 | — | $-0.02 | — | — |
Q2 2021 | May 31, 2021 | — | $-0.03 | — | — |
Latest News
Frequently Asked Questions about RVV.CN
What is RVV.CN's current stock price?
What is the analyst price target for RVV.CN?
What sector is Revive Therapeutics Ltd. in?
What is RVV.CN's market cap?
Does RVV.CN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RVV.CN for comparison